Funding for this research was provided by:
Received: 11 September 2019
Accepted: 20 January 2020
First Online: 28 January 2020
Compliance with ethical standards
: Gaetano Zaccara has received speaker’s or consultancy fees from EISAI, SANOFI, and UCB Pharma. GC is Editor-in-Chief of Intensive Care Medicine and has received honoraria/travel expenses for serving as a speaker for Codman/Integra (2019), Nestle (2018), Neuroptics (2019), and UCB Pharma (2018). ADG has received speaker’s or consultancy fees from UCB Pharma; MF from EISAI, UCB Pharma, and SAGE therapeutics; and FRP from Angelini, Aspen, Astra Zeneca, Bayer, Boeringher, UCB Pharma, Guidotti, Bristol Myers Squibb, Pfizer, and Novartis. DT has also received speaker’s fees from UCB Pharma.